Format

Send to

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2013 Dec;49(12):761-8. doi: 10.1358/dot.2013.49.12.2086995.

Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Author information

1
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA.
2
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA. shaker.mousa@acphs.edu.

Abstract

Pulmonary hypertension (PH) is a progressive disease that is accompanied by a poor prognosis. Pulmonary vasoconstriction is facilitated through multiple pathways and results in increased pulmonary vascular pressure leading to cell proliferation, vascular remodeling, right ventricular hypertrophy/failure, and ultimately death. Until recently, just six medications were approved -all for one subclass of PH. On October 8, 2013, riociguat (AdempasĀ®) became the first medication approved for multiple etiologies of PH. Preclinical studies have demonstrated safety and efficacy with significant clinical trials supporting its advancement into phase IV trials. Although long-term safety and efficacy and place in therapy remain to be established, riociguat presents as an exciting new option for the treatment of PH and potentially has additional indications in the near future.

KEYWORDS:

Chronic thromboembolic arterial hypertension; Pulmonary arterial hypertension; Riociguat; Targeted pathways

PMID:
24524094
DOI:
10.1358/dot.2013.49.12.2086995
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Clarivate Analytics
    Loading ...
    Support Center